BUSINESS SEGMENT INFORMATION (Tables)

6 Months Ended

Jun. 30, 2011

Segment Reporting [Abstract]

Net sales of key products [Text Block]

		Three Months Ended June 30,				Six Months Ended June 30,
Dollars in Millions		2011		2010		2011		2010
PLAVIX*		$	1,865	$	1,627	$	3,627	$	3,293
AVAPRO*/AVALIDE*			251		307		541		621
ABILIFY*			706		633		1,330		1,250
REYATAZ			396		357		762		730
SUSTIVA Franchise			371		331		714		666
BARACLUDE			292		223		567		439
ERBITUX*			173		172		338		338
SPRYCEL			193		132		365		263
YERVOY			95		-		95		-
ORENCIA			228		178		427		347
NULOJIX			2		-		2		-
ONGLYZA/KOMBIGLYZE			112		28		193		38
Mature Products and All Other			750		780		1,484		1,590
	Net Sales	$	5,434	$	4,768	$	10,445	$	9,575

Reconciliation to earnings before income taxes [Text Block]

	Three Months Ended June 30,				Six Months Ended June 30,
Dollars in Millions	2011		2010		2011		2010
BioPharmaceuticals segment income	$	1,299	$	1,180	$	2,587	$	2,413
Reconciling items:
Restructuring and other charges		(68)		(77)		(139)		(332)
Litigation recovery		-		-		102		-
Upfront, milestone and other licensing payments		(50)		(17)		(138)		(72)
In-process research and development impairment		-		-		(15)		-
Product liability charges		-		-		(26)		-
Noncontrolling interest		609		506		1,186		1,035
Earnings before income taxes	$	1,790	$	1,592	$	3,557	$	3,044